Allosterix, LLC Drug-Design and Discovery, Expands Its Scientific Advisory Board and Appoints Prof. Ciechanover, Dr. Havron, Prof. Fishman and Prof. Fridkin

REHOVOT, Israel--(BUSINESS WIRE)--Allosterix Ltd, the Israeli biotechnology company specializing in the design of enzyme inhibitors, today announced the appointment of Professor Aharon Ciechanover, the Nobel Prize laureate; Dr. Avri Havron, Prolor Biotech (AMEX, TASE), CEO; Prof. Pnina Fishman, Can-Fite Biopharma (TASE) CEO; and Prof. Mati Fridkin, peptide chemist expert, The Weizmann Institute, to its Scientific Advisory Board. This further strengthens the Board that includes Dr. Ettie Pirak, the co-inventor of Erbitux; Dr. Raz Zarivach, Ben-Gurion University; and Dr. Ilan Volovitz, Sourasky Medical Center.